Frequency of diencephalic syndrome in NMOSD

Acta Neurol Belg. 2022 Aug;122(4):961-967. doi: 10.1007/s13760-021-01792-1. Epub 2021 Sep 13.

Abstract

Background: Diencephalic region of the brain harbors sites with a considerable amount of aquaporin-4 expression. Neuromyelitis optica spectrum disorder (NMOSD) primarily involves autoimmune processes against this molecule. However, little is known about the frequency of symptoms of diencephalic involvement in NMOSD patients.

Objective: To investigate the frequency of symptoms of diencephalic involvement in NMOSD patients and describe the associated characteristics in patients presenting such symptoms.

Materials and methods: This retrospective cohort included 145 NMOSD patients (39 males and 106 females) who visited Isfahan Multiple Sclerosis Center from January 2013 to February 2020 for approximately 61 months. Demographic and clinical information of patients and findings from radiological and serological investigations were retrieved.

Results: The frequency of diencephalic involvement in NMOSD patients was 3.4% (five cases). Diencephalic syndrome-associated symptoms observed in this cohort consisted of narcolepsy (n = 2; 40%), hypotension (n = 1; 20%), amenorrhea (n = 1; 20%), and syndrome of inappropriate antidiuretic hormone secretion (n = 1; 20%). These manifestations responded well to NMOSD-associated treatments, i.e., rituximab and azathioprine.

Conclusion: Although rarely manifested through symptoms suggestive of diencephalic involvement, NMOSD should be considered when encountering patients with the diencephalic syndrome to identify the primary cause of these manifestations.

Keywords: Diencephalic syndrome; Endocrinopathy; Neuromyelitis optica; Neuromyelitis optica spectrum disorder.

MeSH terms

  • Aquaporin 4
  • Autoantibodies
  • Female
  • Humans
  • Infant, Newborn
  • Male
  • Neuromyelitis Optica* / complications
  • Neuromyelitis Optica* / diagnostic imaging
  • Neuromyelitis Optica* / epidemiology
  • Retrospective Studies
  • Rituximab
  • Syndrome

Substances

  • Aquaporin 4
  • Autoantibodies
  • Rituximab